Journal of Clinical Medicine (May 2023)

Primary Cardiac Schwannoma: A Meta-Analysis of Individual Case Reports

  • Mohamed Rahouma,
  • Massimo Baudo,
  • Sherif Khairallah,
  • Anas Dabsha,
  • Alessandro Tafuni,
  • Magdy M. El-Sayed Ahmed,
  • Christopher Lau,
  • Erin Iannacone,
  • Yoshifumi Naka,
  • Leonard Girardi,
  • Mario Gaudino,
  • Roberto Lorusso,
  • Stephanie L. Mick

DOI
https://doi.org/10.3390/jcm12103356
Journal volume & issue
Vol. 12, no. 10
p. 3356

Abstract

Read online

Primary cardiac schwannoma (PCS) is a neurogenic tumor that arises from Schwann cells. Malignant schwannoma (MSh) is an aggressive cancer comprising 2% of all sarcomas. Information on the proper management of these tumors is limited. Four databases were searched for case reports/series of PCS. The primary outcome was overall survival (OS). Secondary outcomes included therapeutic strategies and the corresponding outcomes. Among 439 potentially eligible studies, 53 met the inclusion criteria. The patients included had 43.72 ± 17.76 years and 28.3% were males. Over 50% of patients had MSh, with 9.4% also demonstrating metastases. Schwannoma commonly occurs in the atria (66.0%). Left-sided PCS were more common than right-sided ones. Surgery was performed in almost 90% of the cases; chemotherapy and radiotherapy were used in 16.9% and 15.1% of cases, respectively. Compared to benign cases, MSh occurs at a younger age and is commonly located on the left side. OS of the entire cohort at 1 and 3 years were 60.7%, and 54.0%, respectively. Females and males OS were similar up to 2 years follow-up. Surgery was associated with higher OS (p < 0.01). Surgery is the primary treatment option for both benign and malignant cases and was the only factor associated with a relative improvement in survival.

Keywords